Axxcess Wealth Management LLC Grows Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Axxcess Wealth Management LLC grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 19.0% in the second quarter, HoldingsChannel reports. The fund owned 12,554 shares of the medical equipment provider’s stock after buying an additional 2,003 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Intuitive Surgical were worth $5,585,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ISRG. Gilbert & Cook Inc. raised its stake in Intuitive Surgical by 6.5% during the fourth quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock worth $1,160,000 after purchasing an additional 211 shares during the period. Financial Advocates Investment Management increased its position in shares of Intuitive Surgical by 6.9% in the fourth quarter. Financial Advocates Investment Management now owns 1,635 shares of the medical equipment provider’s stock worth $552,000 after acquiring an additional 106 shares in the last quarter. AMG National Trust Bank lifted its holdings in shares of Intuitive Surgical by 8.0% during the 4th quarter. AMG National Trust Bank now owns 1,834 shares of the medical equipment provider’s stock valued at $619,000 after acquiring an additional 136 shares in the last quarter. TrinityPoint Wealth LLC raised its position in Intuitive Surgical by 21.5% in the fourth quarter. TrinityPoint Wealth LLC now owns 1,081 shares of the medical equipment provider’s stock valued at $365,000 after purchasing an additional 191 shares during the period. Finally, Hillsdale Investment Management Inc. lifted its stake in shares of Intuitive Surgical by 80.6% during the fourth quarter. Hillsdale Investment Management Inc. now owns 280 shares of the medical equipment provider’s stock worth $94,000 after purchasing an additional 125 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of analyst reports. Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price target for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. Barclays boosted their price objective on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Truist Financial raised their target price on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Citigroup boosted their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, JPMorgan Chase & Co. lifted their price objective on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $446.45.

Insider Activity

In related news, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction on Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the sale, the director now owns 821 shares of the company’s stock, valued at $402,519.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Amy L. Ladd sold 450 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the sale, the director now owns 821 shares of the company’s stock, valued at $402,519.88. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock worth $25,528,753 in the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG opened at $491.39 on Tuesday. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $496.18. The company has a 50-day moving average of $464.67 and a two-hundred day moving average of $422.79. The stock has a market cap of $174.30 billion, a price-to-earnings ratio of 88.70, a PEG ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.18 EPS. Analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.